Prostate Cancer in Male BRCA1 and BRCA2 Mutation Carriers
Author Information
Author(s): Mitra A, Fisher C, Foster C S, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D, Eeles R
Primary Institution: Institute of Cancer Research, Surrey, UK
Hypothesis
The histological characteristics of prostate cancer in male BRCA1 and BRCA2 mutation carriers have not been clearly defined.
Conclusion
Male BRCA1 and BRCA2 mutation carriers with prostate cancer have significantly higher Gleason scores than non-carriers.
Supporting Evidence
- BRCA1/2 mutation carriers had significantly higher Gleason scores than controls.
- The study included a matched control group to minimize bias.
- Histopathological evaluation was conducted by specialist urological pathologists.
Takeaway
Men with certain gene mutations are more likely to have a more serious form of prostate cancer, which means doctors might need to check them more often.
Methodology
Histopathological evaluation of prostate cancer tissue from 20 BRCA1/2 mutation carriers and matched controls.
Potential Biases
Potential bias in matching cases and controls for age, PSA levels, and disease stage.
Limitations
The study may have biases due to the matching process and the variety of sources for tissue samples.
Participant Demographics
Participants included male BRCA1 and BRCA2 mutation carriers with prostate cancer, matched with controls.
Statistical Information
P-Value
0.012
Statistical Significance
p=0.012
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website